Search results for "F68"

showing 2 items of 2 documents

Redistribution, selection, and trade

2017

Abstract This paper examines the distributional effects of international trade in a general equilibrium model with heterogeneous agents and a welfare state redistributing income. The redistribution scheme is financed by a progressive income tax and gives the same absolute transfer to all individuals. Ceteris paribus, international trade leads to an increase in income per capita but also to higher income inequality on two fronts. Inter-group inequality between managers and workers increases, and intra-group inequality within the group of managers goes up as well. We show that for a given tax rate, there is an endogenous increase in the size of the welfare state that works against the increas…

Economics and EconometricsLabour economicsGeneral equilibrium theoryCeteris paribusH24H25International tradeInternational trade Income inequality Redistribution Heterogeneous firmsTax rateEconomic inequalityIncome tax0502 economics and businessEconomicsddc:330F12050207 economicsIncome inequalityD31050205 econometrics 05 social sciencesF16Internationaler Handel Einkommensungleichheit Umverteilung Heterogene FirmenWelfare stateRedistribution (cultural anthropology)Per capita incomeHeterogeneous firmsVolkswirtschaftslehreRedistributionF68Finance
researchProduct

Randomized, placebo-controlled, double-blind and open-label studies in the treatment and prevention of acute diarrhea with Enterococcus faecium SF68

2020

Enterococcus faecium SF68® (SF68) is a licensed pharmaceutical for treatment and prevention of diarrhea in Austria, Italy and Switzerland. However, as for other probiotics, evidence for its efficacy is based on small to medium-sized studies. Four unpublished studies on the treatment of acute diarrhea and the prevention of antibiotic-associated diarrhea were analyzed: one randomized, double blind, placebo-controlled trial (RCT) for treatment (n = 1,143), one open-label study for treatment (n = 5,093), one RCT for prevention (n = 1,397) and one open-label study for prevention (n = 4,340). Patients in the treatment-arm and the open-label studies received SF68 (b.i.d. for the prevention studies…

medicine.medical_specialtyAcute diarrheaEnterococcus faecium610 Medicine & health2700 General Medicinerandomized-controlled trialPlacebolaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialpreventionlawInternal medicinemedicineClinical endpoint030212 general & internal medicineAdverse effectOriginal Researchlcsh:R5-920biologytreatmentbusiness.industryIncidence (epidemiology)SF68acute diarrheaGeneral Medicinebiology.organism_classificationDiarrhea10219 Clinic for Gastroenterology and HepatologyprobioticsMedicine030211 gastroenterology & hepatologymedicine.symptomlcsh:Medicine (General)businessEnterococcus faecium
researchProduct